A Phase 3 interventional study of Nalfurafine HCl 2.5 µg and Nalfurafine HCl 5.0 µg in Uremic Pruritus, sponsored by Acologix, Inc.. Status unknown. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2010-02-04.
Sponsored by Acologix, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing TRK 820 in Pruritus — 3 open to participants now, 3 under way, none of them phase 3. TRK 820 · Pruritus.
Among the 10 studies testing TRK 820 in Pruritus, this one has the largest planned enrollment, is the only one that started in 2009, is one of 3 in phase 3, and was the 2nd registered.
491 studies on the registry are indexed under Pruritus; 94 are open to participants now.
Browse Pruritus studies →3 of the 10 studies testing TRK 820 in Pruritus are open now, in 1 country. Recruiting first, the newest first:
Guangdong Provincial People's Hospital · Sites in China
Ages 18–85
Indonesia University
Ages 18–65
Chinese PLA General Hospital · Sites in China
Ages 18–80
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 54 Pruritus studies recruiting now, 22 (41%) set no upper age limit and 24 (44%) stop at 75 or younger; 15 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2009.
This study's planned enrollment of 350 is above the median of 60 across 423 interventional studies indexed under Pruritus.
Median enrollment 99 across the 10 interventional studies. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 10 have an industry lead sponsor. The 8 most frequent:
Acologix, Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.
Acologix, Inc. has 2 studies filed under Pruritus — fewer than ten, so there is no comparison to draw.
1 of the studies testing TRK 820 in Pruritus that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07098351Guangdong Provincial People's HospitalEfficacy and Safety of Nalfurafine Hydrochloride ODT for Moderate-to-Severe Pruritus in Patients on Peritoneal Dialysis | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing TRK 820 in Pruritus, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary objective of this multicenter, double-blind, placebo controlled, randomized withdrawal study are to determine the effectiveness and safety of orally administered AC-820 in doses of 2.5 µg and 5.0 µg daily in patients with moderate to severe itching associated with end-stage renal disease and hemodialysis, and perform a population PK analysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients will be randomized into Placebo group
Other: Placebo
2.5 µg group randomized
Drug: Nalfurafine HCl 2.5 µg
5.0 µg group randomized
Drug: Nalfurafine HCl 5.0 µg
Daily dose of 2.5 µg
Daily dose of 5.0 µg
Placebo daily dose
Primary efficacy endpoint is the change in worst itching intensity from baseline, compared to that in the last two weeks of the double blind, placebo controlled, randomized withdrawal period.
Time frame: 11 weeks
No study locations are listed for this record.
The record gives a start of Dec 2009, a primary completion of Dec 2010 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TRK 820
Acologix, Inc.